A case of Behcets disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
Modern Rheumatology, 07/20/2011
Hirano T et al. – This treatment suppressed the patient’s clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behcet’s disease.
A 47–year–old female patient with Behcet’s disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab.
Because she relapsed, however, treatment with tocilizumab, a humanized anti–interleukin 6 receptor antibody, was started.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.